A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Takeda
University of Kansas Medical Center
City of Hope Medical Center
Boston University
NantCell, Inc.
National Cancer Institute (NCI)
Tempus AI
Incyte Corporation
Palleon Pharmaceuticals, Inc.
University of Michigan Rogel Cancer Center
Institut Bergonié
OHSU Knight Cancer Institute
NRG Oncology
Elevation Oncology
Daiichi Sankyo
Stanford University
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
VA Office of Research and Development
Pfizer
Exelixis
NextCure, Inc.
Pfizer
Hoffmann-La Roche
pharmaand GmbH
OncoNano Medicine, Inc.
Herlev Hospital
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Gilead Sciences
Institut Bergonié
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Institutes of Health Clinical Center (CC)
Advanced Accelerator Applications
National Institutes of Health Clinical Center (CC)
InSightec
InSightec
Scripps Translational Science Institute
Stanford University
Amgen
Pfizer
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)